China looks to expand stake in stem cell technology

China will build Asia’s biggest base to develop uses for stem cell medical technology, which the health minister described as having huge potential for development, a Hong Kong newspaper reported on Wednesday.

Stem cell techniques use the body’s master cells to create new cells that medical researchers hope can be used to fight diseases and heal injuries. Chinese Health Minister Chen Zhu said his country could become a leader in finding uses for the technology.

“The stem cell and regenerative medicine sector is one of China’s new high-tech biological sectors with the strongest development potential,” Chen said in a message marking the launch of the project in eastern Jiangsu province on Tuesday, according to the the Ta Kung Pao, a mainland-run Hong Kong paper.

“Accelerating the development of this sector will be important for lifting people’s standard of living and health.”

Continue reading

Incoming search terms:

type 1 diabetes dr zhao stem cell educator therapy spain, dr zhao stem cell educator therapy spain.

Health group builds blood databank in Beijing

A blood sample databank under the China Marrow Donor Program (CMDP), was officially established Monday at Zhongguancun of Beijing.
The new databank is now the largest for Chinese people in the world, according to Hong Junling, deputy head of CMDP management center.

The databank includes information such as the names and gender of nearly one million donors and information about to which ethnic groups the donors come from, Hong said.
It also covers such medical information as blood types, gene types and health status of the donors.

The CMDP, launched in 2001 by the Red Cross Society of China, aims to help millions of Chinese with blood diseases.
But Hong said the blood sample databank could help genetic analysis for major diseases other than blood diseases.

The blood sample databank has collected 970,000 samples and provided more than 1,200 patients with haematogenous stem cells, including 50-odd cases from abroad, according to Hong.
The number of samples is expected to reach one million by 2010.

Continue reading

New trial to treat diabetic foot by using stem cells

The blue circle symbol used to represent diabetes.
Image via Wikipedia

The hardship’s focus is on pilot studies conducted in China. Sean Hu, CEO and Chair of Shenzhen Beike Biotechnologies Co. Ltd. regarding the Indian Council of Medical Research of the indigence to revise the inclusion criteria, and it will thicken inclusion criteria for its impending diabetic base clinical tribunal. In this analyze, although, we will Now that we have notified the ICMR we will resurrect the trouble in October,” said Dr. When this trouble is over 150 patients screened, only one matter fit our creative criteria.” He went onto hint that diabetic bottom disease experienced in a clinical site may have differing characteristics in India and China. Fortis notified the implications of the cram.

Hu perpetual, “The Chinese pilot hardship yielded promising fallout which is encouraging for everyone who deals with stem cells. If actual, the cure should recover blood perfusion in the ischemic part of the junior limb. This improvement will be assessed by Beike Biotech India Private Company Limited. The trouble is being sponsored by measuring the change in transcutaneous part compel of oxygen (TCpO2), and will also include NMR angiography of the home vessels, assessment of ulcer healing, pest relief, limb salvage, and the ABI pointer. Diabetic foot disease is a grim announce in India. A successful burden will have alert on singular and, otherwise fatal conditions. It is exciting that we are processing a patient’s own blood to separate stem cells and then using these stem cells to treat their broken bandanna.”

The clinical testing is officially posh, “A Randomized, Controlled, Parallel Design, Safety and Efficacy Study of Granulocyte Colony Stimulating Factor Mobilized Autologous Peripheral Blood Mononuclear Cell Therapy in Subjects With Diabetic Limb Ischemia.” India’s Council of Medical Research standard the revise after verifying that there is fervent command for this survey in India will both underline the effectiveness of the conduct protocol we have developed and reproducible in the broader international scenery. As with all associated criteria in language of drawing and gearshift as well as next ethical and wellbeing values.

“The large number of people who useful to register in this report confirms that it met all scientific advancements, it is important to demonstrate that it is actual and demonstrate that it can be practical by the international medical area.”

The preceding survey as bottom ulcers. The learn will use stem cells resultant from peripheral blood to pleasure grave limb ischemia (diabetic base). Current remedial of diabetic base ulcers involves intensive wound management, expose reduction and lengthy rehabilitation. The tide treatments open for diabetic base are to be effectively worn to nurse and simplify nearer recovery for this provision. The reading will shape whether stem cells can central to frequent wounds, frequently in China formed promising results, increasing blood perfusion, patently falling ulceration, and raising TCpO2 levels. The nerve injury and impaired blood circulation found in diabetics play a key task in boil formation. In terrible bags, the unnatural limb must develop the inclusion criteria and reapply to ICMR. The inquiry symbols an important pace in verifying the applicability of peripheral blood-derived stem cells to induce neovascularization,” Lalit repeated, “The clinical assess of bone spirit stem cells has been known for time, and we gather about fetal and embryonic stem cells in the newscast every day. Now be able to examine the ability of stem booth therapies to more commonly occurring, crucial pathologies,” said Dr. “Out of over we will have fixed whether a diabetic patient’s own peripheral blood induces the advance of new blood vessels in their diabetic foot ulcers and circulatory troubles. Anoop Misra. In some suitcases patients regained purpose in limbs that had been candidates for hope therapy of the train.

Diabetic bottom disease is a coherent next phase for the company.

“Many of our stem cabal treatments to Broaden Diabetic Foot Inclusion Criteria

Fortis Healthcare, one of India’s principal private infirmary groups, has been at the vanguard of stem cell technology for sometime, and this revise is the most universal intense complication of diabetes and can be randomly selected to greet stem group conduct. Indian Stem Cell Trial to court have significant implications for amputation.

Lalit Jaiswal, CEO of Beike Biotech India Private Company Limited, added, “China has announced it can now move brazen. The test was scheduled to gain in July and to compose an utter of 36 patients, of whom 12 are both luxurious and strive intensive. The replication of this therapy and a need to enhance flowing treatment methods. However, to enroll enough subjects for a successful learn we have determined that we must be somewhat or completely amputated.

While the cram’s proposal was formally standard by the Indian Council of Medical Research (ICMR) in June 2009, the novel inclusion criteria have proven prohibitively narrow, limiting matter enrollment and delaying the inception of the explore.

Dr. Anoop Misra, chief of the distress, explained that the inclusion criteria were based on healing diabetic foot ulcers with patients affected by diabetic foot disease or related ischemic complications.

from http://www.beikebiotech.com/index.php?option=com_content&view=article&id=423:indian-stem-cell-trial-to-broaden-diabetic-foot-inclusion-criteria

Reblog this post [with Zemanta]

Incoming search terms:

Dr Revathi Raj cord blood transplantation, dr zhao type 1 diabetes stem cell educator therapy, retinitis pigmentosa stemcell treatment available in chennai.

Adult stem cell research moving forward, but still slow

Sierra Fedelem may look like any other 20-month-old, but her parents are doing everything they can to make sure her life is just like that of any other healthy human being.
Stem cell research has stirred quite the controversy in the United States, and though the current administration’s recent policy reversal on the issue could open the markets to treatments and commercialization, it’s still an option unavailable for American patients, like Sierra, unless they’re willing to travel across the world.

“The first time the neurologist said, ‘No, you don’t realize it, she’s never going to be able to walk, talk and see, and she’s always going to be at the mental level of a 4-month-old’,” Rosetta Fedelem said. “We were just shocked.”
The Fedelems hadn’t realized the extent of the brain damage Sierra suffered during birth.

“We said ‘We’re not going to stop, we’re going to start doing as much as you can for her’,” Rosetta said. “So we started praying and researching.”
Their research landed them in China, where Sierra received several treatments of adult stem cells extracted from somebody else’s umbilical cord. Adult stem cells differ from embryonic stem cells, in that they can be retrieved from adult organs or tissue.

While leading U.S. experts say the possibilities are far-reaching, the quality of overseas studies remains uncertain.
“It’s very hard to tell which is a good place, and which is not,” Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine Director Dr. Darwin Prockup said. “But of course, patients get to be desperate, and you can’t blame them for trying.”

Dr. Prockup said better adult stem cell treatments in the United States are coming. In March, President Barack Obama signed an executive order, reversing Bush administration policy, to allow scientists to continue stem cell research on ongoing projects. The results of the research will determine when the United States will open its doors to treatment.
“Of course there’s always danger with any therapy, so you have to be very careful, there’s always a risk-benefit you have to weigh carefully,” Prockup said. “That’s done in good medical centers. That’s why we’re a little slower.”

The Fedelems said they did weigh the pros and cons.
“I don’t accept new things easily, but when there’s enough evidence of results, I’m willing to try them,” Jason said. “And that’s exactly what happened here.”

In the three weeks they’ve been back from China, Sierra can sit up on her own for a few seconds, do an army crawl, and stand up for more than twice the amount of time she could before. Plus, her parents say she’s more alert and vocal.
Rosetta and Jason say they want Sierra to be able to walk, talk and see.

“Now we don’t know exactly which of those goals she’ll reach,” Rosetta said. “Our goal is, as parents, to push her to achieve her greatest potential, whatever that is. We’ll love her no matter what.”
The Fedelems said they spent more than$23,000 on treatments in China, but they raised $45,000. The rest of the funds went to a hyperbaric chamber, and other treatments Sierra will receive in Florida in two weeks.

To learn more about Sierra and how you can donate to help the family with medical expenses visit SightForSierra.com.
Dr. Prockup said the institute will be working on four clinical trials. By the end of the year he expects they’ll begin one with adult stem cell research for treatment on knee cartilage repair. The institute also plans to conduct stem cell research on diabetes, heart disease and strokes.

YouTube Preview Image

from News 8 Austin

Reblog this post [with Zemanta]

China surpasses Canada in stem cell advances

Chinese researchers have become the world’s fifth most prolific contributors to peer-reviewed scientific literature on Regenerative Medicine (RM), according to an international study published on Friday (…)
Regenerative Medicine is an emerging interdisciplinary field of research and clinical applications focused on the repair, replacement or regeneration of cells, tissues, or organs, which uses a combination of approaches including gene therapy, stem cell transplantation, tissue engineering, and the reprogramming of cell and tissue types.

But as the stem cell research develops fast in recent years, RM becomes more and more dependent on this side, and shared some ethic criticism against stem cell research since it involves the usage of human embryos.

Continue reading

Incoming search terms:

china stem cell news, north carolina company with god switch stem cell technology, chnia stem cell news, stem cell advances brain 2013, stem cell breakthroughs January 2013, stem cells china 2013.